US-based Synapse Biomedical has completed patient enrolment in its post-approval trial of its NeuRx Diaphragm Pacing System (DPS) system for the treatment of amyotrophic lateral sclerosis (ALS).

The system is a four-channel, battery powered neurostimulator with implanted electrodes and it provides electrical stimulation to the muscle and nerves of the diaphragm.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

NeuRx DPS is the only medical device approved by the US Food and Drug Administration (FDA) specifically for ALS patients.

This humanitarian device secured approval at the end of 2011 with the demonstration of safety and probable benefit.

"NeuRx DPS is the only medical device approved by the US FDA specifically for ALS patients."

The post-approval study, validating the safety, is also intended to help identify the patient population that may benefit most from this therapy.

See Also:

Synapse Biomedical president and chief executive officer Anthony Ignagni said: "When we see the impact that this device can have for individual patients, we know that providing this supporting therapy is meaningful for ALS patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Our FDA approval demonstrated the safety of the device and provided evidence of improvements in survival and sleep for these patients.

"It is our mission to make the NeuRx DPS available for the people with this devastating disease and to continue to advance the knowledge base of how and who to best use it in."

The NeuRx technology was originated at Case Western Reserve University and University Hospitals Case Medical Center (UHCMC) for spinal cord injured patients and further it was developed by Synapse for ALS patients.

UHCMC chair of Surgical Innovation and Synapse Biomedical co-founder Raymond Onders said: "DPS has a proven safe role in maintaining respiration in ALS patients with one of our initial pilot patients using DPS for six years without the need for invasive ventilation."